Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-14-005682
Filing Date
2014-08-12
Accepted
2014-08-12 16:45:01
Documents
10
Period of Report
2014-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0614_actinium.htm 10-Q 386391
2 BY LAWS f10q0614ex3i_actinium.htm EX-3.1 91265
3 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNT f10q0614ex31i_actinium.htm EX-31.1 12945
4 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNT f10q0614ex32i_actinium.htm EX-32.1 5666
  Complete submission text file 0001213900-14-005682.txt   4807697

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE atnm-20140630.xml EX-101.INS 569433
6 XBRL SCHEMA FILE atnm-20140630.xsd EX-101.SCH 61975
7 XBRL CALCULATION FILE atnm-20140630_cal.xml EX-101.CAL 22721
8 XBRL DEFINITION FILE atnm-20140630_def.xml EX-101.DEF 228212
9 XBRL LABEL FILE atnm-20140630_lab.xml EX-101.LAB 497804
10 XBRL PRESENTATION FILE atnm-20140630_pre.xml EX-101.PRE 323091
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 141034499
SIC: 6770 Blank Checks